Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk

Despite recent advances in the development of tools to predict immunogenicity risk of biotherapeutic molecules, the ability of a protein to elicit the formation of anti-drug antibodies (ADA) remains one of the most common causes for termination of clinical development programs. In this study, we use...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:MAbs
Autors principals: Bivi, Nicoletta, Moore, Terry, Rodgers, George, Denning, Heather, Shockley, Travis, Swearingen, Craig A., Gelfanova, Valentina, Calderon, Boris, Peterson, Daniel A., Hodsdon, Michael E., Siegel, Robert W., Higgs, Richard E., Konrad, Robert J.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2019
Matèries:
Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6601536/
https://ncbi.nlm.nih.gov/pubmed/31099718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2019.1612699
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars